An update on repurposed medications for the treatment of drug-resistant tuberculosis.

abstract：:Schizophrenia is a major mental illness with a lifetime prevalence of about 1%. Antipsychotic drugs, with a primary mechanism of action that involves dopamine receptor blockade, are the mainstay in the treatment of the disorder. However, despite optimum antipsychotic treatment, few patients return to pre-morbid levels...

journal_title：Expert review of clinical pharmacology

authors： Andrade C

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:Betalactams are the most widely used drugs against infections and the primary cause of antibiotic hypersensitivity reactions. Reaction patterns for different betalactams have been changing in accordance with consumption trends, and vary among countries. As a consequence, in vivo and in vitro tests have had...

journal_title：Expert review of clinical pharmacology

authors： Fernandez TD,Mayorga C,Salas M,Barrionuevo E,Posadas T,Ariza A,Laguna JJ,Moreno E,Torres MJ,Doña I,Montañez MI

更新日期：2017-06-01 00:00:00

abstract：:'IDegLira' combines insulin degludec (IDeg) with the glucagon-like peptide-1 analog liraglutide (Lira) at a ratio of 1 unit IDeg to 0.036 mg Lira. The two components have complementary therapeutic actions for the treatment of Type 2 diabetes. Studies have shown that combinations of basal insulin with glucagon-like pep...

journal_title：Expert review of clinical pharmacology

authors： Simpson R,King A

更新日期：2015-03-01 00:00:00

abstract：:Gout is an inflammatory arthritis characterized by sudden, painful inflammation. Gout can affect any joint in an asymmetric distribution. Gouty attacks may be isolated or can be followed by years of recurrent flares. Over time, elevated serum urate levels and tophaceous deposits can lead to deformity and disability fr...

journal_title：Expert review of clinical pharmacology

authors： Dave AJ,Kelly VM,Krishnan E

更新日期：2012-09-01 00:00:00

abstract：:Introduction: In September of 2018, the United States Federal Drug Administration (FDA) approved cemiplimab-rwlc (Libtayo) for advanced cutaneous squamous cell carcinoma (CSCC). Cemiplimab is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1). Cemiplimab blocks T-cell ina...

journal_title：Expert review of clinical pharmacology

authors： Ahmed SR,Petersen E,Patel R,Migden MR

更新日期：2019-10-01 00:00:00

abstract：INTRODUCTION:A new five-year low dose, smaller-framed, levonorgestrel-releasing intrauterine contraceptive system (LNG-IUS 12) has been introduced to complement the currently available systems. Areas Covered: This article will provide an overview of this new intrauterine system - its composition and its mechanisms of a...

journal_title：Expert review of clinical pharmacology

authors： Nelson AL

更新日期：2017-08-01 00:00:00

abstract：:Oncology is one of the areas of medicine with the most active research being conducted on new drugs. New pharmacological entities frequently enter the clinical arena, and therefore, the safety profile of anticancer products deserves continuous monitoring. However, only very severe and (unusual) suspected adverse drug ...

journal_title：Expert review of clinical pharmacology

authors： Tuccori M,Montagnani S,Capogrosso-Sansone A,Mantarro S,Antonioli L,Fornai M,Blandizzi C

更新日期：2015-01-01 00:00:00

abstract：INTRODUCTION:Long-acting injectable antipsychotics (LAIAs) were introduced to improve treatment adherence and tolerability of oral formulations. After risperidone was introduced as the first long-acting injectable second-generation antipsychotic, during the last five years olanzapine pamoate, once-monthly paliperidone ...

journal_title：Expert review of clinical pharmacology

authors： Bernardo M,Bioque M

更新日期：2016-07-01 00:00:00

abstract：INTRODUCTION:The immune system can restrain or promote cancer development and growth. Antibodies targeting immune checkpoints have revolutionized cancer treatment. Among the best responses have been in non-small cell lung cancer (NSCLC) which is largely caused by chronic exposure to carcinogens; associated with high ne...

journal_title：Expert review of clinical pharmacology

authors： Santini FC,Rudin CM

更新日期：2017-09-01 00:00:00

abstract：:Migraine is a common neurological syndrome that affects approximately 10-20% of the population. The pathophysiology of migraine is unclear. 5-hydroxytriptamine is a key mediator in the pathogenesis of migraine and thus 5-HT1-receptor agonists are the principal drugs for acute migraine therapy. There are three classes ...

journal_title：Expert review of clinical pharmacology

authors： Reddy DS

更新日期：2013-05-01 00:00:00

abstract：INTRODUCTION:Osteoarthritis constitutes one of the leading causes of pain and disability worldwide with a significant impact on health-care costs. Patients with osteoarthritis are often affected by a number of cardiovascular comorbidities, including hypertension, which is present in about 40% of cases. Just recently, a...

journal_title：Expert review of clinical pharmacology

authors： Angeli F,Trapasso M,Signorotti S,Verdecchia P,Reboldi G

更新日期：2018-11-01 00:00:00

abstract：INTRODUCTION:Therapeutic efficiency of NSAID is handicapped by ongoing discussion of cardiovascular (CV) safety. Areas covered: We update meta-analyses on NSAIDs in patients with and without cardiovascular (CV) diseases and analyse the association between NSAIDs and cardiovascular events in patients with inflammation. ...

journal_title：Expert review of clinical pharmacology

authors： Zingler G,Hermann B,Fischer T,Herdegen T

更新日期：2016-11-01 00:00:00

abstract：:Acetaminophen (APAP)/paracetamol is one of the most commonly used over-the-counter drugs taken worldwide for treatment of pain and fever. Although considered as safe when taken in recommended doses not higher than 4 g/day, APAP overdose is currently the most important cause of acute liver failure (ALF). ALF may requir...

journal_title：Expert review of clinical pharmacology

authors： Tiegs G,Karimi K,Brune K,Arck P

更新日期：2014-09-01 00:00:00

abstract：:The use of pharmacokinetic (PK) and pharmacodynamic (PD) data to inform antimalarial treatment regimens has accelerated in the past few decades, due in no small part to the stimulus provided by progressive development of parasite resistance to most of the currently available drugs. An understanding of the disposition,...

journal_title：Expert review of clinical pharmacology

authors： Davis TM,Moore BR,Salman S,Page-Sharp M,Batty KT,Manning L

更新日期：2016-01-01 00:00:00

abstract：INTRODUCTION:The broad use of immunotherapy is revolutionizing the treatment paradigms of many solid tumors. Although chemotherapy remains the treatment backbone for advanced gastric cancer, improvements in its molecular characterization and progresses in understanding its underpinning biology have supported clinical d...

journal_title：Expert review of clinical pharmacology

authors： Bonotto M,Garattini SK,Basile D,Ongaro E,Fanotto V,Cattaneo M,Cortiula F,Iacono D,Cardellino GG,Pella N,Fasola G,Antonuzzo L,Silvestris N,Aprile G

更新日期：2017-06-01 00:00:00

abstract：:Contraceptive management in women with epilepsy is critical owing to the potential maternal and fetal risks if contraception or seizure management fails. This article briefly describes the pharmacokinetic interactions between antiepileptic drugs (AEDs) and hormonal contraceptives and the rational strategies that may o...

journal_title：Expert review of clinical pharmacology

authors： Reddy DS

更新日期：2010-03-01 00:00:00

abstract：:Chronic diarrhea remains a common condition that affects people infected with human immunodeficiency virus (HIV) despite the widespread use of potent antiretroviral therapy. It is important that providers control this condition, as the persistence of diarrhea affects the quality of life of patients and may contribute ...

journal_title：Expert review of clinical pharmacology

authors： Castro JG,Chin-Beckford N

更新日期：2015-01-01 00:00:00

abstract：:Second-generation antipsychotics (SGA) have been associated with risk of stroke in elderly patients, but the molecular and genetic background under this association has been poorly investigated. The aim of the present study was to prioritize a list of genes with an SGA altered expression in order to characterize the g...

journal_title：Expert review of clinical pharmacology

authors： Cocchi E,Drago A,de Ronchi D,Serretti A

更新日期：2014-01-01 00:00:00

abstract：:Alzheimer's disease is the most common cause of dementia and is becoming a global health concern. Despite a well-established understanding of the molecular mechanism involved in its pathogenesis, and millions of dollars of investment in drug discovery and clinical trials, no single molecule has yet been approved for i...

journal_title：Expert review of clinical pharmacology

authors： Léger GC,Massoud F

更新日期：2013-07-01 00:00:00

abstract：INTRODUCTION:In the modern antimicrobial era, the rapid spread of resistance to antibiotics and introduction of new and mutating viruses is a global concern. Combating antimicrobial resistant microbes (AMR) requires coordinated international efforts that incorporate new conventional antibiotic development as well as de...

journal_title：Expert review of clinical pharmacology

authors： Enioutina EY,Teng L,Fateeva TV,Brown JCS,Job KM,Bortnikova VV,Krepkova LV,Gubarev MI,Sherwin CMT

更新日期：2017-11-01 00:00:00

abstract：:Introduction: Combined antiretroviral therapy (cART) has transformed an inexorably fatal disease into a chronic pathology, shifting the focus of research from the control of viral replication to the possibility of HIV cure. Areas covered: The present review assesses the principal pharmacological strategies that have b...

journal_title：Expert review of clinical pharmacology

authors： Giacomelli A,de Rose S,Rusconi S

更新日期：2019-01-01 00:00:00

abstract：INTRODUCTION:In pediatric pharmacotherapy, many drugs are still used off-label, and their efficacy and safety is not well characterized. Different efficacy and safety profiles in children of varying ages may be anticipated, due to developmental changes occurring across pediatric life. AREAS COVERED:Beside pharmacokine...

journal_title：Expert review of clinical pharmacology

authors： Brussee JM,Calvier EA,Krekels EH,Välitalo PA,Tibboel D,Allegaert K,Knibbe CA

更新日期：2016-09-01 00:00:00

abstract：:The aim of this article was to assess the efficacy and safety of apremilast in treatment of psoriatic arthritis (PsA) with meta-analysis method. We included four randomized clinical trials identified from MEDLINE, EMBASE, Cochrane Library, "ISRCTN Register" and "ClinicalTrials.gov" which compared apremilast with place...

journal_title：Expert review of clinical pharmacology

authors： Qu X,Zhang S,Tao L,Song Y

更新日期：2016-06-01 00:00:00

abstract：INTRODUCTION:Allogeneic hematopoietic cell transplants (allo-HCT) recipients are at the high-risk of reactivation of cytomegalovirus (CMV), and reactivation is associated with significant morbidity and mortality. Although available anti-CMV therapies may be effective for the prevention of CMV, they are plagued by unacc...

journal_title：Expert review of clinical pharmacology

authors： Foolad F,Aitken SL,Chemaly RF

更新日期：2018-10-01 00:00:00

abstract：:Introduction: Patients with early HER2-positive breast cancer (BC) benefit from HER2-targeted systemic therapy. The endorsed standard adjuvant treatment for patients with early HER2-positive breast cancer is chemotherapy plus trastuzumab administered for 1 year. Areas covered: Several trials have investigated modifica...

journal_title：Expert review of clinical pharmacology

authors： Esposito A,Viale G,Criscitiello C,Curigliano G

更新日期：2019-01-01 00:00:00

abstract：:The last decades were characterized by enormous technological advances resulting in a better understanding of disease pathologies and improvement of treatment strategies. The development of targeted drugs, whose beginning can be traced back to Paul Ehrlich's theory of the 'magic bullet' approximately 100 years ago, is...

journal_title：Expert review of clinical pharmacology

authors： Hebar A,Valent P,Selzer E

更新日期：2013-01-01 00:00:00

abstract：INTRODUCTION:Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin. Despite the known clinical efficacy in relapsed/refractory acute myeloid leukemia (AML), GO was withdrawn from the market in 2010 due to increased e...

journal_title：Expert review of clinical pharmacology

authors： Baron J,Wang ES

更新日期：2018-06-01 00:00:00

abstract：OBJECTIVES:To estimate the prevalence of polypharmacy (≥5 drugs) among adults and to analyze related factors. METHODS:Cross-sectional study with 1,159 interviewees distributed across 104 cities and 253 primary healthcare services delivered through the Brazilian Unified Health System. Polypharmacy-related factors were ...

journal_title：Expert review of clinical pharmacology

authors： Moreira T,Alvares-Teodoro J,Barbosa MM,Do Nascimento RCRM,Guerra Júnior AA,Acurcio FA

更新日期：2020-12-01 00:00:00

abstract：:RNAi is a powerful gene silencing process that holds great promise in cancer therapy by the use of siRNA. The aim of this review is to give an outline on different approaches to deliver siRNA and to describe the advantages and disadvantages of these systems. The prospects for siRNA are to be substantially better than ...

journal_title：Expert review of clinical pharmacology

authors： Ali HM,Urbinati G,Raouane M,Massaad-Massade L

更新日期：2012-07-01 00:00:00

abstract：:The problem of adverse drug reactions is a well-documented global public health problem. Recent withdrawals of several widely used prescription medications in the USA and other countries have raised concerns among patients, clinicians, scientists and policy makers. The increasing interest and concern regarding withdra...

journal_title：Expert review of clinical pharmacology

authors： Issa AM

更新日期：2008-03-01 00:00:00